NYSE:LLY

Eli Lilly and Price Target, Predictions & Analyst Ratings

$325.62

+12.90 (+4.13%)

(As of 06/24/2022 07:00 PM ET)

Add

Compare

Today's Range: $319.01
▼
$325.82
50-Day Range: $278.73
▼
$325.62
52-Week Range: $220.20
▼
$325.82

Volume: 5.45 million shs
Average Volume: 3.03 million shs
Market Capitalization: $309.39 billion

P/E Ratio: 48.24
Dividend Yield: 1.20%
Price Target: $311.65

Eli Lilly and (NYSE:LLY) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 17 Analyst Ratings

Consensus Analyst Price Target

$311.65
-4.29% Downside

High Price Target	$369.00
Average Price Target	$311.65
Low Price Target	$264.00

Type	Current 6/27/21 to 6/27/22	1 Month Ago 5/28/21 to 5/28/22	3 Months Ago 3/29/21 to 3/29/22	1 Year Ago 6/27/20 to 6/27/21
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	14 Buy rating(s)	15 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$311.65	$307.94	$293.06	$221.42
Predicted Upside	-4.29% Downside	15.22% Upside	13.58% Upside	14.47% Upside

Get Eli Lilly and Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Stock vs. The Competition

Type	Eli Lilly and	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.71	2.52
Consensus Rating	Moderate Buy	Buy	Buy
Predicted Upside	-4.29% Downside	439.12% Upside	29.94% Upside
News Sentiment Rating	Neutral News	Neutral News	Neutral News
MarketBeat Community Rating	Outperform Votes 1092 71.56% Underperform Votes 434 28.44%	Avg. Outperform Votes 170 66.93% Avg. Underperform Votes 84 33.07%	Avg. Outperform Votes 839 69.11% Avg. Underperform Votes 375 30.89%

Historical Eli Lilly and Price Targets and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/1/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$340.00 ➝ $355.00	+13.26%
5/23/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$341.00	+14.10%
5/2/2022	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$315.00 ➝ $356.00	+21.86%
4/29/2022	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$364.00 ➝ $369.00	+24.13%
4/29/2022	Wells Fargo Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$280.00 ➝ $305.00	+2.60%
4/12/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$234.00 ➝ $264.00	-14.55%
3/17/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$300.00 ➝ $315.00	+13.95%
3/10/2022	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$286.00	+8.83%
1/21/2022	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Elmar Kraus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$291.00	+19.69%
1/3/2022	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$250.00 ➝ $300.00	+11.40%

12/20/2021	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$270.00 ➝ $305.00	+14.05%
12/20/2021	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$280.00 ➝ $325.00	+21.53%
12/16/2021	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$311.00 ➝ $320.00	+16.30%
11/24/2021	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robyn Karnauskas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$262.00 ➝ $301.00	+14.90%
9/29/2021	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$210.00 ➝ $265.00	+19.58%
8/30/2021	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$250.00 ➝ $300.00	+15.50%
8/9/2021	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$225.00 ➝ $300.00	+13.88%
6/24/2021	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Positive ➝ Overweight	$245.00 ➝ $300.00	+26.03%
12/10/2020	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$147.00 ➝ $183.00	+15.82%
6/16/2020	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$182.00	+28.60%
4/24/2020	Cfra Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold	$146.00 ➝ $167.00	+2.83%
4/20/2020	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$157.00 ➝ $158.00	+0.13%

(Data available from 6/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Eli Lilly and Price Target - Frequently Asked Questions

What is Eli Lilly and's consensus rating and price target?: According to the issued ratings of 17 analysts in the last year, the consensus rating for Eli Lilly and stock is Moderate Buy based on the current 3 hold ratings and 14 buy ratings for LLY. The average twelve-month price prediction for Eli Lilly and is $311.65 with a high price target of $369.00 and a low price target of $264.00. Learn more on LLY's analyst rating history.
Do Wall Street analysts like Eli Lilly and more than its competitors?: Analysts like Eli Lilly and stock more than the stock of other Medical companies. The consensus rating for Eli Lilly and is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how LLY compares to other companies.
Do MarketBeat users like Eli Lilly and more than its competitors?: MarketBeat users like Eli Lilly and stock more than the stock of other Medical companies. 71.56% of MarketBeat users gave Eli Lilly and an outperform vote while medical companies recieve an average of 67.07% outperform votes by MarketBeat users.

Does Eli Lilly and's stock price have much upside?: According to analysts, Eli Lilly and's stock has a predicted upside of 14.78% based on their 12-month price targets.
What analysts cover Eli Lilly and?: Eli Lilly and has been rated by JPMorgan Chase & Co., Mizuho, Morgan Stanley, SVB Leerink, The Goldman Sachs Group, and Wells Fargo in the past 90 days.

This page (NYSE:LLY) was last updated on 6/27/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Just $1.00 for your first month.

Eli Lilly and Price Target, Predictions & Analyst Ratings

Eli Lilly and (NYSE:LLY) Price Target and Consensus Rating (2022)

Consensus Analyst Rating

Consensus Analyst Price Target

LLY Stock Analyst Ratings By Month

LLY Stock Price Target by Month

Eli Lilly and Stock vs. The Competition

Historical Eli Lilly and Price Targets and Ratings

Eli Lilly and Price Target - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources